Company Statement on Aflibercept

Fri, 29 Dec 2023
Posted by: Biocon Biologics
Download Company Statements

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

“In the matter of Regeneron Pharmaceuticals, Inc. v Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. (Case No. 22-061), the U.S. District Court for the Northern District of West Virginia issued a mixed decision pertaining to three of Regeneron’s patents purporting to cover certain formulations and methods of treatment relating to the ophthalmic product, EYLEA® (aflibercept) Injection. The court decided that certain claims of the method of treatment patents (U.S. Patent Nos. 10,888,601 and 11,253,572) were invalid, while certain claims of the formulation patent (U.S. Patent No. 11,084,865) were held valid and infringed.

Biocon Biologics is an innovation-driven company and will continue to aggressively pursue its mission of bringing high-quality affordable biosimilars to patients in the United States.” – Company Spokesperson

For more information email: seema.ahuja@biocon.com

Author:
Biocon Biologics

You are now leaving Biocon Biologics U.S., a Biocon Biologics website. The website you are about to access is not owned or controlled by Biocon Biologics Inc.

Biocon Biologics Inc. assumes no responsibility for and makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Biologics, and a link to this website from another website does not imply a relationship between Biocon Biologics and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party’s terms and policies (including its privacy policy). Biocon Biologics shall not be liable for any direct, indirect, consequential, incidental, or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.

OK
CANCEL

You are now departing from the Biocon Biologics U.S. website and redirected to the Biocon Biologics corporate website. Please be aware that the Biocon Biologics corporate website may contain information that varies from the content on the Biocon Biologics U.S. website. The website you are about to access is the corporate website located outside of U.S.
U.S. regulations may not be applicable to the content on this corporate website.

OK
CANCEL